RxSight

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded by Robert Grubbs and Daniel Schwartz on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

RxSight reports stellar Q2 results, raises guidance amid strategic focus

RxSight's Q2 2023 performance reflects robust revenue growth and margin improvement, supported by strong LAL sales. While challenges like net losses persist, the company's strategic focus on technology and market growth presents promising opportunities for future success.

RxSight reports stellar Q3 results, eyes profitability and product expansion

RxSight's Q3 performance reflects robust revenue growth, driven by strong LAL sales and operational efficiency improvements, positioning the company for future success.
With a focus on innovation and product efficacy, RxSight's strategic strengths lie in their ability to meet market demand and drive revenue through expanded offerings.
While challenges in managing expenses and sustaining growth persist, RxSight's financial strength and market opportunities signal a promising outlook for profitability and value creation.

RxSight reports strong revenue growth driven by LAL sales

RxSight's Q4 2023 performance showcased robust revenue growth driven by LAL sales, despite increased operating expenses and a net loss.
The company's strong cash position, debt-free status, and focus on innovation position it well for future revenue growth and market expansion.
Challenges include managing expenses, navigating complex international markets, and optimizing product mix for sustained profitability.
Opportunities lie in European market expansion, investor engagement, and leveraging technology to drive adoption and revenue growth.

RxSight reports robust Q1 revenue growth, faces expense challenges

RxSight's Q1 2024 performance reflects strong revenue growth and improved gross margin, yet challenges persist with increasing expenses and net loss.
The company's focus on LAL technology, guidance increase, and market expansion efforts present opportunities for future growth and market penetration.
To address challenges, RxSight needs to balance cost management with innovation and capitalize on opportunities in adoption trends and international markets.

RxSight reports robust Q2 earnings, eyes international expansion for growth

RxSight's Q2 performance reflects strong revenue growth, improved margins, and strategic investments in growth areas.
While facing rising expenses, RxSight's focus on premium products, international expansion, and innovation positions it for future success.
Challenges in cost management and market dynamics require careful navigation, but opportunities in product expansion and market penetration are promising.
Overall, RxSight's financial outlook remains positive, supported by a strong cash position and a clear growth strategy.

RxSight posts robust Q4 results, eyes growth through innovation

RxSight's Q4 2024 performance reflects strong revenue growth, record sales, and improved profitability, positioning the company for future success. While facing challenges in achieving profitability, RxSight's solid financial foundation, focus on innovation, and market opportunities offer avenues for growth. By managing expenses effectively, investing in key areas, and leveraging its innovative technology, RxSight can capitalize on market opportunities and drive continued growth.

RxSight reports Q2 revenue decline, eyes international expansion for growth

RxSight's Q2 2025 performance saw a revenue decline but maintained a strong gross margin of 74.9%. The company faces challenges in revenue growth and profitability but has opportunities in market expansion and cost control. By focusing on LAL utilization, customer success, and international expansion, RxSight aims to drive future growth and profitability.

RxSight reports Q3 revenue decline, focuses on efficiency and expansion

RxSight's Q3 performance saw revenue decline but gross margin improvement. Challenges include declining LDD sales and increased operating expenses. Opportunities lie in international expansion, educating physicians, and efficiency enhancements.

RxSight reports Q4 sales decline, eyes rebound with LAL technology

RxSight's Q4 2025 performance reflected a decline in total sales but a notable increase in LAL sales and gross margin, positioning the company for future growth. Despite facing challenges such as lower LDD sales and a net loss in 2025, RxSight's strengths in financial stability, innovation, and strategic focus present opportunities for long-term success. By focusing on rebounding sales growth, international expansion, and technology advancements, RxSight aims to drive profitability and solidify its position in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.